Aging and the Mitochondrial Response to Exercise Training, Measured by Noninvasive 31P Magnetic Resonance Spectroscopy (MoTrMito)

Education Daily Report

2021 MAR 30 (NewsRx) -- By a News Reporter-Staff News Editor at Education Daily Report -- Staff editors report on the newly launched clinical trial, NCT04799171, which has the following summary description: “The goal of the study is to determine whether aerobic or resistant exercise can improve in vivo mitochondrial capacity of skeletal muscle cells similarly in healthy younger, middle aged and older adults. This confers long-term changes in this tissue which in-turn contribute to improved metabolic health and functional capacity through epigenetic regulation of novel exercise response genes.”

As a matter of record, on March 17, 2021, NewsRx staff editors report that the available information provided by Pennington Biomedical Research Center on this trial include:

Tracking Information

Trial Identifier	NCT04799171
First Submitted Date	March 11, 2021
First Posted Date	March 16, 2021
Results First Submitted Date	Not Provided
Results First Posted Date	Not Provided
Last Update Submitted Date	March 11, 2021
Last Update Posted Date	March 16, 2021
Primary Completion Date	July 31, 2024
Start Date	April 2021
Current Primary Outcome Measures	•Pre-training 31P MRS measurement - Phosphocreatine recovery rate [ Time Frame: Baseline visit - before any muscle biopsies or exercise training. ] -- The plot of PCr peak height vs. time will be fitted with a mono-exponential equation whose free parameters are the recovery time constant (tau) and scaling coefficients. Percent change in tau between pre- and post-intervention scans will be our primary measurement of the maximal mitochondrial capacity response to exercise training.
	•Post-training 31P MRS measurement - Phosphocreatine recovery rate [ Time Frame: After week 12 visit - after all muscle biopsies and exercise training. ] -- The plot of PCr peak height vs. time will be fitted with a mono-exponential equation whose free parameters are the recovery time constant (tau) and scaling coefficients. Percent change in tau between pre- and post-intervention scans will be our primary measurement of the maximal mitochondrial capacity response to exercise training.
Current Secondary Outcome Measures	Not Provided
Other Outcome Measures	Not Provided
Change History	Complete list of historical revisions of study NCT04799171

Descriptive Information

Brief Title	Aging and the Mitochondrial Response to Exercise Training, Measured by Noninvasive 31P Magnetic Resonance Spectroscopy
Official Title	Aging and the Mitochondrial Response to Exercise Training, Measured by Noninvasive 31P Magnetic Resonance Spectroscopy (MoTrMito)
Brief Summary	The goal of the study is to determine whether aerobic or resistant exercise can improve in vivo mitochondrial capacity of skeletal muscle cells similarly in healthy younger, middle aged and older adults. This confers long-term changes in this tissue which in-turn contribute to improved metabolic health and functional capacity through epigenetic regulation of novel exercise response genes.
Detailed Description	This goal of the study is to understand the biological pathways and molecules driving the exercise response variation of the muscle mitochondria in vivo to elucidate the underlying mechanisms for the health benefits of exercise training in young, middle aged and older adults. This knowledge will improve our understanding of biological basis for targeted “precision medicine” exercise and non-exercise interventions to improve age related conditions. The mitochondrial capacity measurement via non-invasive 31P magnetic resonance spectroscopy (31-MRS) will provide a tangible link between the two primary foci of the parent MoTrPAC study: molecular drivers of exercise response and key phenotypic health outcomes.
Study Type	Interventional
Study Phase	N/A
Study Design	Allocation: Randomized
	Intervention Model: Parallel Assignment
	Primary Purpose: Other
	Masking: None (Open Label)
Condition	Physical Activity
Intervention	•Other: Isometric Contraction Exercise - Young Adults (Age group 18-39)
	Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, we instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
	•Other: Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)
	Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, we instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
	•Other: Isometric Contraction Exercise - Old Adults (Age group >60)
	Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, we instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
Study Arms	•Active Comparator: Middle Aged Adults (Age group 40-59)
	31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
	Interventions:
	⚬Other: Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)
	•Active Comparator: Old Adults (Age group >60)
	31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
	Interventions:
	⚬Other: Isometric Contraction Exercise - Old Adults (Age group >60)
	•Active Comparator: Young Adults (Age group 18-39)
	31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
	Interventions:
	⚬Other: Isometric Contraction Exercise - Young Adults (Age group 18-39)

Recruitment Information

Recruitment Status	Not yet recruiting
Estimated Enrollment	420
Estimated Completion Date	July 2024
Primary Completion Date	July 31, 2024 (Final data collection date for primary outcome measure)
Eligibility	Inclusion Criteria: ADULT PARTICIPANT INCLUSION CRITERIA
	•YOUNG PARTICIPANTS
	•Willingness to provide informed consent to participate in the MoTrMito Study Must be able to read and speak English well enough to provide informed consent and understand instructions Aged18
	•39 y Body Mass Index (BMI) >19 to <35 kg/m2 ADULT PARTICIPANT INCLUSION CRITERIA
	•MIDDLE AGE PARTICIPANTS Willingness to provide informed consent to participate in the MoTrMito Study Must be able to read and speak English well enough to provide informed consent and understand instructions Aged 40
	•59 y BMI >19 to <35 kg/m2 ADULT PARTICIPANT INCLUSION CRITERIA
	•OLD AGE PARTICIPANTS Willingness to provide informed consent to participate in the MoTrMito Study Must be able to read and speak English well enough to provide informed consent and understand instructions Aged >=60 y BMI >19 to <35 kg/m2 Exclusion Criteria: ADULT PARTICIPANT EXCLUSION CRITERIA Exclusion criteria are confirmed by either self-report (i.e., medical and medication histories reviewed by a clinician), screening tests performed by the MoTrMito study team at each clinical site, and/or clinician judgement as specified for each criterion. Diabetes (self-report and screening tests) Treatment with any hypoglycemic agents (self-report) or A1c >6.4 (screening test; may reassess once if 6.5-6.7) Fasting glucose >125 (screening test; may reassess once) Use of hypoglycemic drugs (e.g., metformin) for non-diabetic reasons (self-report) Abnormal bleeding or coagulopathy (self-report) ◦History of a bleeding disorder or clotting abnormality Thyroid disease (screening test) Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment Pulmonary (self-report) ◦Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Metabolic bone disease (self-report) History of non-traumatic fracture from a standing height or less Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen Estrogens, progestins (self-report) ◦Supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms Pregnancy (screening test) and pregnancy-related conditions (self-report) Pregnant
	•pregnancy test performed on day of DXA scan in women of child-bearing potential Post-partum during the last 12 months Lactating during the last 12 months Planning to become pregnant during the participation period Elevated blood pressure readings (screening test) Aged <60 years: Resting Systolic Blood Pressure (SBP) ≥140 mmHg or Resting Diastolic Blood Pressure (DBP) ≥90 mmHg Aged ≥60 years: Resting SBP ≥150 mmHg or Resting DBP ≥90 mmHg Reassessment of BP during screening will be allowed to ensure rested values are obtained Cardiovascular (self-report, screening test, and clinician judgement) Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, or symptomatic peripheral artery disease (self-report, screening test) Specific criteria used to determine whether a volunteer can undergo the screening Cardiopulmonary Exercise Test (CPET) follow the American Heart Association (AHA) Criteria [54] Inability to complete the CPET Abnormal blood lipid profile (screening test) Fasting triglycerides >500 mg/dL Low-density lipoprotein cholesterol (LDL-C) >190mg/dL Cancer (self-report) History of cancer treatment (other than non-melanoma skin cancer) and not “cancer-free” for at least 2 years Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months Chronic infection (self-report) Infections requiring chronic antibiotic or anti-viral treatment Human Immunodeficiency Virus Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded Liver enzyme tests (Alanine transaminase, Aspartate transaminase) (screening test) ◦>2 times the laboratory upper limit of normal Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen) Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting Chronic renal insufficiency (screening test) Estimated glomerular filtration rate <60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult) Hematocrit (screening test) Hematocrit >3 points outside of the local normal laboratory ranges for women and men Reassessment may be allowed under certain conditions Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting Individuals with known thalassemia trait may be included (despite having >3 points outside of the local normal laboratory ranges), upon approval from their PCP or a hematologist Blood donation (self-report) Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period Autoimmune disorders (self-report) ◦Individuals receiving any active treatment (including monoclonal antibodies) within the last 6 months Alcohol consumption (self-report) More than 7 drinks per week for women More than 14 drinks per week for men History of binge drinking (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month) Tobacco (self-report) ◦Self-reported use ≥3 days/week of tobacco or e-cigarette/e-nicotine products Marijuana (self-report) ◦Self-reported use ≥3 days/week in any form Shift workers (self-report) Night shift work in the last 6 months Planning night shift work during the study period Cognitive status (screening) ◦Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the local investigator Psychiatric illness (self-report and screening test) Hospitalization for any psychiatric condition within one year (self-report) Center for Epidemiological Studies-Depression Scale (CESD) score ≥16 [55] (screening test) Weight change (self-report) Weight change (intentional or not) over the last 6 months of >5% of body weight Plan to lose or gain weight during the study Lidocaine or other local anesthetic (self-report) ◦Known allergy to lidocaine or other local anesthetic Other (clinician judgement) Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol EXCLUSIONS FOR MEDICATION USE Use of any new drug in the last 3 months Dose change for any drug in the last within 3 months Cardiovascular Beta blockers and centrally acting anti-hypertensive drugs (clonidine, guanfacine and alpha-methyl-dopa) Anticoagulants (coumadin or Direct Oral Anticoagulants) Antiarrhythmic drugs: amiodarone, dronaderone, profafenone, disopyrimide, quinidine Antiplatelet drugs (other than aspirin ≥100 mg/day): dipyridamole, clopidogrel, ticagrelor Lipid-lowering medications Participants who volunteer to stop lipid-lowering medications for the duration of the study are allowed; inclusion requires lipid-lowering medication to be stopped for 3 months and participant re-evaluated for LDL-C eligibility Psychiatric drugs Chronic use of medium or long-acting sedatives and hypnotics (short-acting non-benzodiazepine sedative-hypnotics are allowed) All benzodiazepines Tricyclic antidepressants at a dose ≥75 mg total dose per day Two or more drugs for depression Mood stabilizers Antiepileptic drugs Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs Muscle relaxants ◦Methacarbamol; cyclobenzaprine; tizanidine; baclofen Pulmonary, inflammation Chronic oral steroids Burst/taper oral steroids more than once in the last 12 months B2-agonists allowed if on stable dose at least 3 months Genitourinary Finasteride or dutasteride Daily phosphodiesterase type 5 inhibitor use Hormonal Testosterone, dehydroepiandrosterone, anabolic steroids Anti-estrogens, anti-androgens Growth hormone, insulin like growth factor-I, growth hormone releasing hormone Any drugs used to treat diabetes mellitus or to lower blood glucose Metformin for any indication Any drugs used specifically to induce weight loss Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy Pain/inflammation Narcotics and narcotic receptor agonists Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen ≥3 days per week Other Anti-malarials Low-potency topical steroids if ≥10% of surface area using rule of 9s Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion
Sex/Gender	Sexes Eligible for Study: All
Ages	18 years and older
Accepts Healthy Volunteers	Yes
Contacts	Primary contact: Melissa Harris, 2257633091, [email protected]
	Backup contact: Owen T Carmichael, PhD, 2257632989, [email protected]
Listed Location Countries	Not Provided
Removed Location Countries

Administrative Information

NCT Number	NCT04799171
Other Study ID Numbers	PBRC 20-03
Has Data Monitoring Committee	Not Provided
U.S. FDA-regulated Product	Not Provided
Plan to Share Data	No
Plan to Share Data (IPD) Description	As a MoTrPAC ancillary study, we will comply with all regulations of the MoTrPAC Ancillary Study Committee regarding sharing of data generated from MoTrPAC participants. We will follow up on any data irregularities identified by the Bioinformatics Core as part of their data cleaning process. The Bioinformatics Core will then make our MRS summary data ancillary study data to the community together with the MoTrPAC main study data and data from any other ancillary studies that arise. We are familiar with the NIH policies regarding data sharing, and during our data transfer to the main MoTrPAC study we will comply with local, state, and federal laws, such as the Privacy Rule, a Federal regulation under the Health Insurance Portability and Accountability Act (HIPAA).
Responsible Party	Owen Carmichael, Pennington Biomedical Research Center
Collaborators	⚬University of Colorado, Denver
	⚬University of Pittsburgh
	⚬The University of Texas Health Science Center at San Antonio
	⚬Translational Research Institute for Metabolism and Diabetes, Florida
	⚬Stanford University
	⚬Wake Forest University Health Sciences
Investigators	Principal Investigator: Owen T Carmichael, PhD, Director, Biomedical Imaging Center, PBRC
Information Provided By	Pennington Biomedical Research Center
Verification Date	March 2021

(Our reports deliver fact-based news of research and discoveries from around the world.)

Older

Fact-check: Is the surge of migrant children arriving at border a result of Biden policies?

Newer

Pennsylvania's 2022 U.S. Senate race: Who's in, who's out and what comes next

Advisor News

More Advisor News

Annuity News

More Annuity News

Health/Employee Benefits News

More Health/Employee Benefits News

Life Insurance News

Sponsor

More Life Insurance News